Alternation in glucagon secretion by Sodium glucose transporter-2 inhibitor

Not Applicable

• Conditions: Type2 diabetes mellitus; Type2 deabetes mellitus; C18.452.394.750.149

• Registration Number: JPRN-jRCTs031190010
• Lead Sponsor: Ichikawa Raishi

Brief Summary

It has been suggested that SGLT-2 inhibitors may act directly on pancreatic alpha cells to increase glucagon secretion, so we hypothesized that SGLT-2 inhibitors contribute to improved glycemic control by altering glucagon secretion. To test this hypothesis, we conducted meal tolerance test before and after administrated SGLT-2 inhibitors in adult type 2 diabetes patients who managed with diet and exercise to determine whether glucagon secretion changed after food intake. For further validation, we also exa

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-04-16
• Study Completion: 2020-07-10
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Type 2 (non-insulin dependent) diabetes patients, aged 20 to 79, who are controlled in diet and exercise, and glycated Hb(HbA1c) is 7.0% or above and 10.0% or below.

Exclusion Criteria

1. A patient suffering from acute disease
2. In case of malignacy
3. Renal dysfunction (estimeted GFR <60ml/min)
4. Liver dysfunction (AST >100U/l, ALT >100U/l)
5. Pregnant or possibility of pregnant
6. Lactating mothers
7. A patient suffering from endocrine disorders
8. A patient administrated any drugs affect glucose metabolism
9. Diabetic patients who have taken any hypoglycemic agents include SGLT-2 inhibitor in proximate 6 months
10.A patient undergoing or having history of treatment for ischemic heart disease
11.Chronic heart failure (NYHA class 2 or worse)
12.A patient undergoing or having history of treatment for cerebro-vascular disease
13.A patient undergoing or multiple (3 times or more) history of urinary or genital tract infection
14.A patient accompanied with severe diabetic retinopathy, nephropathy, neuropathy
15.A patient in hyperglycemic crisis or accompanied with marked symptom of hyperglycemia
16.Taking diuretics
17.Correspond to contraindication of Luseogliflozin

Study & Design

• Study Type: Interventional
• Study Design: Not specified